Marker Therapeutics, Inc.
MRKR
$1.43
$0.021.06%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -43.87% | -46.19% | -12.99% | 44.55% | 71.52% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -43.87% | -46.19% | -12.99% | 44.55% | 71.52% |
| Cost of Revenue | -17.98% | -12.39% | 34.05% | 65.78% | 45.89% |
| Gross Profit | 4.29% | -25.08% | -85.58% | -85.29% | -37.92% |
| SG&A Expenses | -7.91% | -1.34% | -4.93% | -18.52% | -32.69% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -15.58% | -9.74% | 22.57% | 36.30% | 14.12% |
| Operating Income | 5.51% | -15.00% | -44.82% | -36.67% | -1.97% |
| Income Before Tax | 14.31% | -14.02% | -47.95% | -41.28% | -4.30% |
| Income Tax Expenses | -130.40% | -130.40% | 1,251.35% | 1,251.35% | 1,251.35% |
| Earnings from Continuing Operations | 14.77% | -13.35% | -48.42% | -41.72% | -4.67% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 14.77% | -13.35% | -47.45% | -40.86% | -125.79% |
| EBIT | 5.51% | -15.00% | -44.82% | -36.67% | -1.97% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 50.15% | 24.87% | -12.57% | -16.87% | -108.00% |
| Normalized Basic EPS | 48.28% | 27.90% | -9.04% | -13.62% | 7.51% |
| EPS Diluted | 50.12% | 24.95% | -12.28% | -16.56% | -106.83% |
| Normalized Diluted EPS | 48.28% | 27.90% | -9.04% | -13.62% | 7.51% |
| Average Basic Shares Outstanding | 82.00% | 70.32% | 43.12% | 21.46% | 7.64% |
| Average Diluted Shares Outstanding | 82.00% | 70.32% | 43.12% | 21.46% | 7.64% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |